Advertisement
IQV vs MEDP
Which Stock Would AI Choose? IQVIA Holdings Inc. (IQV) vs. Medpace Holdings, Inc. (MEDP) Stock Comparison
Key Takeaways
- IQVIA Holdings Inc. (IQV) operates as a large-scale provider of clinical research services, commercial insights, and healthcare intelligence, while Medpace Holdings, Inc. (MEDP) focuses primarily on contract research organization (CRO) services for clinical trials.
- In recent market activity, IQV has delivered modest year-to-date gains near 8.5%, contrasting with MEDP’s year-to-date decline of approximately 4.3%.
- Both companies face upcoming second-quarter 2026 earnings reports, with IQV scheduled for July 28 and MEDP for July 22, which may influence near-term sentiment.
- MEDP has shown stronger one-year returns around 68% compared to IQV’s roughly 26%, highlighting differences in recent momentum.
- IQV maintains broader exposure across data analytics and life sciences support, whereas MEDP’s model emphasizes full-service clinical development with potentially higher operational efficiency in its niche.
- Market positioning reflects trade-offs between scale and specialization within the healthcare services sector.
Introduction
IQVIA Holdings Inc. (IQV) and Medpace Holdings, Inc. (MEDP) represent two distinct approaches within the healthcare and life sciences services industry. This comparison examines their business models, recent stock behavior, and relative positioning to assist traders and investors evaluating exposure to clinical research and data-driven healthcare solutions. Market participants seeking to understand sector-specific dynamics, growth trajectories, and valuation contrasts may find this analysis relevant amid ongoing developments in biopharmaceutical outsourcing and regulatory environments.
IQV Overview and Recent Performance
IQVIA Holdings Inc. (IQV) delivers clinical research services, commercial insights, and healthcare intelligence to life sciences and healthcare clients. In recent weeks, the stock has traded in a range influenced by broader healthcare sector movements and anticipation surrounding its second-quarter 2026 earnings release scheduled for July 28. Year-to-date performance stands near 8.5%, with one-year returns around 26%. Recent market activity has featured modest fluctuations, supported by the company’s diversified backlog and ongoing demand for data analytics capabilities. Sentiment has been shaped by investor focus on earnings visibility and sector rotation within healthcare services.
MEDP Overview and Recent Performance
Medpace Holdings, Inc. (MEDP) provides contract research organization services centered on clinical trial management for pharmaceutical and biotechnology sponsors. In recent weeks, the stock has reflected mixed momentum ahead of its second-quarter 2026 results expected on July 22. Year-to-date performance shows a decline of approximately 4.3%, though one-year returns remain strong near 68%. Recent market activity has been affected by valuation considerations and positioning ahead of earnings, with the company’s focused clinical development model continuing to attract attention from growth-oriented investors. Sentiment remains tied to trial pipeline strength and operational execution in a competitive CRO landscape.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots drawn from hundreds available on the platform. These bots trade thousands of different tickers across varied strategies, timeframes, and performance profiles. Only those demonstrating the strongest alignment with prevailing market conditions earn placement in the trending section. Available bots exhibit a wide range of statistics, including differing win rates, profit factors, and drawdown metrics that appeal to diverse trading preferences. All AI trading bots feature unique combinations of trading styles, strategies, timeframes, performances, statistics, and sets of tickers they trade. Review the full selection on the Trending AI Robots page for additional details.
Head-to-Head Comparison
IQVIA Holdings Inc. (IQV) and Medpace Holdings, Inc. (MEDP) operate in overlapping yet differentiated segments of the healthcare services sector. IQV’s broader platform integrates clinical trials with data analytics and commercial insights, offering scale advantages and diversified revenue streams. MEDP maintains a more specialized full-service CRO model that can deliver higher operational efficiency in clinical development. Recent momentum favors MEDP on a one-year basis, while IQV has shown steadier year-to-date results. Risk factors include earnings volatility for both, with IQV exposed to larger client concentration and MEDP to trial-specific execution risks. Sector exposure centers on biopharma outsourcing demand, though IQV’s analytics component provides additional insulation from pure clinical cyclicality. Market sentiment reflects these contrasts, with investors weighing growth consistency against valuation multiples in the current environment.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings visibility, and relative positioning, Tickeron’s AI models currently assign a modestly higher probability of favorable near-term behavior to IQV. This assessment draws from IQV’s broader diversification and steadier recent performance metrics compared with MEDP’s sharper longer-term gains offset by recent underperformance. Outcomes remain probabilistic and subject to earnings results and sector developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IQV is a Hold and MEDP is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IQV’s FA Score shows that 0 FA rating(s) are green whileMEDP’s FA Score has 2 green FA rating(s).
- IQV’s FA Score: 0 green, 5 red.
- MEDP’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IQV’s TA Score shows that 6 TA indicator(s) are bullish while MEDP’s TA Score has 5 bullish TA indicator(s).
- IQV’s TA Score: 6 bullish, 3 bearish.
- MEDP’s TA Score: 5 bullish, 3 bearish.
Price Growth
IQV (@Medical Specialties) experienced а +0.87% price change this week, while MEDP (@Medical Specialties) price change was +11.84% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.55%. For the same industry, the average monthly price growth was +2.80%, and the average quarterly price growth was +1.12%.
Reported Earning Dates
IQV is expected to report earnings on Jul 28, 2026.
MEDP is expected to report earnings on Oct 26, 2026.
Industries' Descriptions
@Medical Specialties (-1.55% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| IQV | MEDP | IQV / MEDP | |
| Capitalization | 34.7B | 16.8B | 207% |
| EBITDA | 3.52B | 591M | 595% |
| Gain YTD | -7.702 | 7.074 | -109% |
| P/E Ratio | 25.84 | 35.33 | 73% |
| Revenue | 16.6B | 2.68B | 620% |
| Total Cash | 2.1B | 653M | 322% |
| Total Debt | 16.1B | 122M | 13,197% |
IQV | MEDP | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 85 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 65 Fair valued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 26 | |
SMR RATING 1..100 | 42 | 15 | |
PRICE GROWTH RATING 1..100 | 43 | 38 | |
P/E GROWTH RATING 1..100 | 62 | 41 | |
SEASONALITY SCORE 1..100 | 65 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IQV's Valuation (65) in the Servicestothe Health Industry industry is in the same range as MEDP (80) in the Miscellaneous Commercial Services industry. This means that IQV’s stock grew similarly to MEDP’s over the last 12 months.
MEDP's Profit vs Risk Rating (26) in the Miscellaneous Commercial Services industry is significantly better than the same rating for IQV (100) in the Servicestothe Health Industry industry. This means that MEDP’s stock grew significantly faster than IQV’s over the last 12 months.
MEDP's SMR Rating (15) in the Miscellaneous Commercial Services industry is in the same range as IQV (42) in the Servicestothe Health Industry industry. This means that MEDP’s stock grew similarly to IQV’s over the last 12 months.
MEDP's Price Growth Rating (38) in the Miscellaneous Commercial Services industry is in the same range as IQV (43) in the Servicestothe Health Industry industry. This means that MEDP’s stock grew similarly to IQV’s over the last 12 months.
MEDP's P/E Growth Rating (41) in the Miscellaneous Commercial Services industry is in the same range as IQV (62) in the Servicestothe Health Industry industry. This means that MEDP’s stock grew similarly to IQV’s over the last 12 months.
| IQV | MEDP | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 56% | 3 days ago 86% |
| Stochastic ODDS (%) | 3 days ago 63% | 3 days ago 80% |
| Momentum ODDS (%) | 3 days ago 64% | 3 days ago 75% |
| MACD ODDS (%) | 3 days ago 50% | 3 days ago 83% |
| TrendWeek ODDS (%) | 3 days ago 61% | 3 days ago 76% |
| TrendMonth ODDS (%) | 3 days ago 63% | 3 days ago 76% |
| Advances ODDS (%) | 3 days ago 60% | 17 days ago 76% |
| Declines ODDS (%) | 5 days ago 65% | 7 days ago 63% |
| BollingerBands ODDS (%) | 3 days ago 66% | 3 days ago 76% |
| Aroon ODDS (%) | 3 days ago 57% | 3 days ago 76% |
Advertisement
IQV and
Correlation & Price change
A.I.dvisor indicates that over the last year, IQV has been closely correlated with CRL. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if IQV jumps, then CRL could also see price increases.
| Ticker / NAME | Correlation To IQV | 1D Price Change % | ||
|---|---|---|---|---|
| IQV | 100% | +0.35% | ||
| CRL - IQV | 75% Closely correlated | -1.18% | ||
| TMO - IQV | 71% Closely correlated | -0.71% | ||
| MEDP - IQV | 65% Loosely correlated | -0.73% | ||
| RVTY - IQV | 64% Loosely correlated | -2.39% | ||
| A - IQV | 62% Loosely correlated | -0.84% | ||
More | ||||
MEDP and
Correlation & Price change
A.I.dvisor indicates that over the last year, MEDP has been loosely correlated with CRL. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MEDP jumps, then CRL could also see price increases.
| Ticker / NAME | Correlation To MEDP | 1D Price Change % | ||
|---|---|---|---|---|
| MEDP | 100% | -0.73% | ||
| CRL - MEDP | 53% Loosely correlated | -1.18% | ||
| TMO - MEDP | 47% Loosely correlated | -0.71% | ||
| BRKR - MEDP | 43% Loosely correlated | -2.74% | ||
| RVTY - MEDP | 39% Loosely correlated | -2.39% | ||
| ICLR - MEDP | 39% Loosely correlated | -2.68% | ||
More | ||||